Tonix Pharmaceuticals Holding Corp. Annual report pursuant to Section 13 and 15(d)

STOCK BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2016

A summary of the stock option activity and related information for the Plans for the years ended December 31, 2016, and 2015 is as follows:

	Shares			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at January 1, 2015		122,680		$	124.04			$	-
Grants		51,324		$	60.13				-
Exercised		-
Forfeitures or expirations		(8,340	)		81.67
Outstanding at January 1, 2016		165,664		$	106.38		8.35	$	1,125,299
Grants		69,800		$	46.58			$	-
Exercised		-
Forfeitures or expirations		(18,038	)		57.00
Outstanding at December 31, 2016		217,426		$	91.33		7.82	$	-
Vested and expected to vest at December 31, 2016		217,426		$	91.33		7.82	$	-
Exercisable at December 31, 2016		131,277		$	115.51		7.19	$	-

The assumptions used in the valuation of stock options granted during the years ended December 31, 2016 and 2015 were as follows:

	2016	2015
Risk-free interest rate	0.85% to 2.25%	1.47% to 2.35%
Expected term of option	6.0 to 9.06 years	6.0 to 9.91 years
Expected stock price volatility	73.46% to 81.59%	80.91% to 92.13%

The following table summarizes the RSU activity for the years ended December 31, 2016 and 2015:

Unvested restricted stock units as of January 1, 2015	-
Granted	4,200
Forfeited	-
Vested	-
Unvested restricted stock units as of January 1, 2016	4,200
Granted	11,250
Forfeited	-
Vested	(4,200	)
Unvested restricted stock units as of December 31, 2016	11,250